For a blood cancer, one of the standard treatments has long been to take blood out. People with polycythemia vera, a chronic condition where the bone marrow makes too many red blood cells, go in again and again for phlebotomy, a procedure that looks a lot like donating blood, to keep their red cell counts and the clot risk that comes with them in check. On August 28 the FDA approved a drug that tries a different route, and the trial behind it gives a fairly clear picture of what the drug does and where the evidence stops.
The drug is Mimrylo, generically rusfertide, discovered by Protagonist Therapeutics and brought to market by Takeda. The FDA called it the first of its kind for polycythemia vera, and “kind” is a specific thing here: a hepcidin mimetic. Hepcidin is the hormone the body uses to regulate iron, and Mimrylo imitates it, cutting the iron available for building red blood cells. Takeda describes the approach as targeting the iron dysregulation underneath the overproduction, rather than draining the excess afterward. It’s a once-weekly injection under the skin, started at 19 milligrams and adjusted to keep hematocrit, the share of blood made up of red cells, under 45%, which is the main treatment goal in this disease.
The approval rests on VERIFY, a phase 3 trial of 293 adults who still needed frequent phlebotomies despite standard treatment. Half received Mimrylo and half received placebo, and everyone kept their usual therapy on top. From week 20 to week 32, 76.9% of people on Mimrylo didn’t need a phlebotomy, compared with 32.9% on placebo, a common risk difference of 43.8 percentage points, with a confidence interval running from 33.5 to 54.2.
The second figure deserves as much attention as the first. A third of the placebo group got through those same twelve weeks without needing a phlebotomy either, so the drug’s contribution is the difference between the two numbers, not the 76.9 on its own. That difference is still large, and it’s the one the trial was designed to test. Takeda also reports less fatigue among treated patients, though that comes from the company’s own summary.
On safety, injection site reactions and anemia were the most commonly reported problems, and Takeda’s safety summary describes most events as mild or moderate. The dose is adjusted against hematocrit, with 45% as the line to stay under.
A few points tend to get flattened in headlines. This isn’t the first treatment for polycythemia vera. Phlebotomy has been the backbone for years, and medicines like Jakafi and Besremi already exist, so “first of its kind” describes the mechanism, not the disease. For patients the swap is a weekly injection in place of periodic blood draws, which some will welcome and others won’t. And the double-blind comparison lasted 32 weeks. The full study runs 156 weeks and is still going, so how well control holds up over years, and whether it changes outcomes like clots, isn’t settled by the data behind this approval.
It lands alongside other 2026 cancer-treatment stories where the mechanism is the news, from a blood pressure pill that makes an existing therapy hit harder to an antibody for prostate cancer aimed at one signaling receptor. Mimrylo’s version is about supply: limit the iron and the marrow has less to build with.
The FDA’s Tanya Wroblewski framed the problem as long meaning “frequent blood draws” in the course of managing a chronic blood disorder. For anyone living that routine, the useful thing to bring to a hematologist is a count: how many phlebotomies the past year took, and whether hematocrit stayed under 45%, because that’s exactly the situation VERIFY enrolled.
